The Bioguard VLabs tests for the screening of Vector-borne diseases in dogs.

The Bioguard VLabs tests for the screening of Vector-borne diseases in dogs.

Vector-borne diseases (VBD) are infections transmitted by the bite of infected arthropod species, such as mosquitoes, ticks, triatomine bugs, sandflies, and blackflies. (VBD) are a growing global threat, it’s one of "a group of globally distributed and rapidly spreading illnesses.

Many VBD’s are transmissible to humans as well as companion animals, Companion vector-borne diseases (CVBDs) have among others a major impact on the welfare of pets. They may also represent a constant risk to humans due to their zoonotic nature, which emphasizes the importance of pets as reservoirs.

Some CVBD’s are fatal; most can only be controlled, not cured. Some can even lead to death if left untreated, Bioguard in the fight against the VBD and the challenges of CVBD diagnosis has developed the VLabs 4X (CHW, Lyme, Anaplasma, E. Canis) and VLabs 4BX (CHW, B. Gibsoni, Anaplasma, E. Canis) for the detection of the most common VBD’s in dogs.

The Bioguard VLabs 4X and 4BX are simple, accurate, and reliable for testing CVBD’s in your practice.

Pandemic-era pet industry surpasses record-breaking $100 billion in sales

Pet industry sales in the United States exceeded $100 billion for the first time ever in 2020, despite and in some ways due to repercussions of the COVID-19 pandemic and consumer trends. Total pet industry revenue totaled $103.6 billion in 2020, with pet food and treat sales leading the pack at $42 billion. This represents a strong 9.7% increase from 2019 for pet food and treats sales.veterinary care and product sales represented $31.4 billion in sales, up 7.2% from 2019, while sales of supplies, live animals and over-the-counter (OTC) medications totaled $22.1 billion, up 15.1%.

Bioguard will participate in the global BIO Digital 2021

The Bioguard Corporation, as a part of Taiwan Pavilion, announces participation in the coming BIO Digital 2021 on June 10-11 & 14-18, 2021.

The Bioguard actively participates in the BIO International Convention, the biggest worldwide biological conventions in North America, yearly. As the convention went virtual last year due to the global situation brought by the pandemic, this year’s virtual convention is expected to bring global biotech industries to showcase their innovative technology.

During the convention, the Biotechnology Innovation Organization (BIO) will feature events: BIO One-on-One Partnering™; Interactive Education; and an Innovation Stage for a new interactive networking series. With thousands of attendees and innovators, Bioguard will be joining and will showcase our very own innovative technology.

With the said event, BIO- revolution through global partnerships, collaboration, and thought leadership shall be accelerated. The non-stop innovation despite the current global situation shall advance and come to discovery.

Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV)

Unlike some forms of viruses that infect cells and then kill them, FeLV and FIV actually alter the genetic material of the infected cell and turn cells into little virus factories. This process takes time, so in both cases, cats may be infected for many years before becoming clinically ill.

FeLV and FIV in cats are serious and unfortunately incurable diseases, the best way to prevent the spread of these diseases is to have your cat tested regularly.

The Bioguard VETlabs Feline leukemia Virus (FeLV) Ag/ Feline immunodeficiency Virus (FIV) Ab Combo Test is a sandwich lateral flow immunochromatographic assay, developed by Bioguard Corporation for enabling the simplicity of rapidly testing or detecting the feline leukemia virus antigen and feline immunodeficiency Virus antibody in cat’s blood.

Learn more